Article by Professor Johnny Ludvigsson on clinical trials with Diamyd® published in Expert Opinion on Biological Therapy

A peer-reviewed article of published research and registered ongoing trials using GAD-alum (Diamyd ® ) has been published in the scientific journal Expert Opinion on Biological Therapy. The article is authored by Professor Johnny Ludvigsson at Linköping University in Sweden who is the principal investigator of several of the on-going studies with Diamyd ® . In the article, he highlights the safety, ease of use and tolerability of the therapy and that there is a strong probability that Diamyd ® has efficacy. This efficacy needs to be improved, for example through combination therapies and new approaches for administration.

The abstract of the article GAD65: a prospective vaccine for treating Type 1 diabetes? is available on http://www.tandfonline.com/doi/abs/10.1080/14712598.2017.1328495  

Five clinical trials with Diamyd ® are ongoing. As previously announced, a follow up pivotal Phase II trial where Diamyd ® is administered directly into the lymph node is expected to start at selected clinics in some countries in Europe including Sweden this fall.

About Diamyd Medical
Diamyd Medical is dedicated to finding a cure for diabetes and other serious inflammatory diseases through pharmaceutical development and investments in stem cell and medical technology.

Diamyd Medical develops the diabetes vaccine Diamyd ® , an antigen-specific immunotherapy based on the exclusively licensed GAD-molecule. Five clinical trials are ongoing with Diamyd ® . An exclusive license comprising the therapeutic use of GABA in diabetes and inflammatory diseases constitutes alongside with the diabetes vaccine a key asset and the Company is developing a proprietary GABA drug product. Diamyd Medical is one of the major shareholders in the stem cell company NextCell Pharma AB and has holdings in the medtech company Companion Medical, Inc., San Diego, USA and in the gene therapy company Periphagen, Inc., Pittsburgh, USA.

Diamyd Medical’s B-share is traded on Nasdaq First North under the ticker DMYD B. FNCA Sweden AB is the Company’s Certified Adviser. Further information is available on the Company’s website: www.diamyd.com.  

For further information, please contact:
Ulf Hannelius, President and CEO
Phone: +46 736 35 42 41
E-mail: ulf.hannelius@diamyd.com

Diamyd Medical AB (publ)
Kungsgatan 29, SE-111 56 Stockholm, Sweden. Phone: +46 8 661 00 26, Fax: +46 8 661 63 68
E-mail: info@diamyd.com. Reg. no.: 556242-3797. Website:  www.diamyd.com

This information is information that Diamyd Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 16:15 CET on May 10, 2017.

Tags:

About Us

Diamyd Medical is a Swedish diabetes company dedicated to finding a cure for autoimmune diabetes through pharmaceutical development and investments in stem cell- and medical technology.

Subscribe

Documents & Links